ProCE Banner Activity

HER3-Targeted Therapies for EGFRm NSCLC: Emerging Therapies and Challenges in Treatment

Clinical Thought

Explore this expert-authored commentary on emerging HER3-targeted therapies as promising treatment strategies for EGFRm NSCLC, particularly in patients with acquired resistance to EGFR TKIs.

Released: October 09, 2024

Expiration: October 08, 2025

Share

Faculty

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Karen Reckamp, MD, MS: consultant/advisor/speaker: AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novacure, Novartis; researcher (paid to institution): Blueprint, Daiichi Sankyo, Elevation Oncology, Genentech, Janssen.